105 related articles for article (PubMed ID: 15650451)
21. [Application of radiolabeled anti-HBx monoclonal antibody for HCC targeting therapy].
Li J; Tang Z; Liu K
Zhonghua Yi Xue Za Zhi; 1996 Apr; 76(4):271-4. PubMed ID: 8758272
[TBL] [Abstract][Full Text] [Related]
22. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
23. Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma.
Brans B; Van Laere K; Gemmel F; Defreyne L; Vanlangenhove P; Troisi R; Van Vlierberghe H; Colle I; De Hemptinne B; Dierckx RA
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):928-32. PubMed ID: 12111134
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
25. Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma.
Zhang Z; Bian H; Feng Q; Mi L; Mo T; Kuang A; Tan T; Li Y; Lu W; Zhang Y; Zhang M; Tian R; Chen Z; Zhu P
Cancer Biol Ther; 2006 Mar; 5(3):318-22. PubMed ID: 16481737
[TBL] [Abstract][Full Text] [Related]
26. [Biological distribution of 131I-HAb18F(ab')2 in patients with hepatocellular carcinoma].
Lu W; Li X; Wang C; Liu W; Jiao H; Mo T; Chen Z
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Dec; 20(4):689-91. PubMed ID: 14716878
[TBL] [Abstract][Full Text] [Related]
27. Observation of changes in peripheral T-lymphocyte subsets by flow cytometry in patients with liver cancer treated with radioimmunotherapy.
Zeng ZC; Tang ZY; Liu KD; Yu YQ; Yang BH; Cai XJ; Xie H; Cao SL
Nucl Med Commun; 1995 May; 16(5):378-85. PubMed ID: 7659390
[TBL] [Abstract][Full Text] [Related]
28. Milestones in the development of Lym-1 therapy.
DeNardo GL; O'Donnell RT; Rose LM; Mirick GR; Kroger LA; DeNardo SJ
Hybridoma; 1999 Feb; 18(1):1-11. PubMed ID: 10211782
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma (HCC)].
Li KD
Zhonghua Zhong Liu Za Zhi; 1992 Nov; 14(6):430-2. PubMed ID: 1338985
[TBL] [Abstract][Full Text] [Related]
30. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
31. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.
DeNardo GL; DeNardo SJ; Lamborn KR; Goldstein DS; Levy NB; Lewis JP; O'Grady LF; Raventos A; Kroger LA; Macey DJ; McGahan JP; Mills SL; Shen S
Cancer Biother Radiopharm; 1998 Aug; 13(4):239-54. PubMed ID: 10850360
[TBL] [Abstract][Full Text] [Related]
32. Quantitation of alpha-fetoprotein messenger RNA for early detection of recurrent hepatocellular carcinoma: a prospective pilot study.
Schmilovitz-Weiss H; Stemmer SM; Liberzon E; Avigad S; Sulkes J; Belinki A; Kazatsker A; Ben-Ari Z
Cancer Detect Prev; 2006; 30(2):204-9. PubMed ID: 16638626
[TBL] [Abstract][Full Text] [Related]
33. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
[TBL] [Abstract][Full Text] [Related]
34. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
[TBL] [Abstract][Full Text] [Related]
35. Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).
Tschmelitsch J; Barendswaard E; Williams C; Yao TJ; Cohen AM; Old LJ; Welt S
Cancer Res; 1997 Jun; 57(11):2181-6. PubMed ID: 9187118
[TBL] [Abstract][Full Text] [Related]
36. A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control.
Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Zahir MH; Salouti M; Rajabi AB; Mazidi M
Hum Antibodies; 2010; 19(4):79-88. PubMed ID: 21178279
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant 131I-anti-CEA-antibody radioimmunotherapy inhibits the development of experimental colonic carcinoma liver metastases.
Mahteme H; Lövqvist A; Graf W; Lundqvist H; Carlsson J; Sundin A
Anticancer Res; 1998; 18(2A):843-8. PubMed ID: 9615730
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of combined (131)I-chTNT and radiofrequency ablation therapy in treating advanced hepatocellular carcinoma.
Tu J; Ji J; Wu F; Wang Y; Zhang D; Zhao Z; Ying X
Cell Biochem Biophys; 2015 Mar; 71(2):777-84. PubMed ID: 25293788
[TBL] [Abstract][Full Text] [Related]
40. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
Order SE; Stillwagon GB; Klein JL; Leichner PK; Siegelman SS; Fishman EK; Ettinger DS; Haulk T; Kopher K; Finney K
J Clin Oncol; 1985 Dec; 3(12):1573-82. PubMed ID: 2415692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
